NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRADON (anisindione) is an oral anticoagulant belonging to the indandione class, approved in 1957 for thromboembolism prevention. It functions as a vitamin K antagonist similar to warfarin, inhibiting hepatic synthesis of clotting factors II, VII, IX, and X. The drug is indicated for patients requiring long-term anticoagulation therapy.
LOE Approaching
Minimal commercial activity expected as product approaches loss of exclusivity with low market share relative to modern DOACs; brand team likely in maintenance mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MIRADON represents a legacy asset with minimal career development opportunity; linked job count is zero, reflecting the product's marginal commercial importance and approaching LOE. Professionals assigned to this product should view it as a consolidation or maintenance role rather than a growth opportunity.
Regulatory Affairs SpecialistProduct Manager
Worked on MIRADON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.